
Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma
Keywords: ACC; adrenocortical carcinoma; IGF-1R; IGF-1 receptor; PI3K; PI3 kinase; mTOR; mammalian target of rapamycin; Adrenal; Cancer; Pharmacology; Signalling;